25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

CTKB (Cytek Biosciences Inc) Stock Analysis
Buy, Hold or Sell?

Let's analyze Cytek Biosciences Inc together

I guess you are interested in Cytek Biosciences Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • 📊 Fundamental Analysis (FA) – Cytek Biosciences Inc’s Financial Insights
  • 📈 Technical Analysis (TA) – Cytek Biosciences Inc’s Price Targets

I'm going to help you getting a better view of Cytek Biosciences Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Cytek Biosciences Inc

I send you an email if I find something interesting about Cytek Biosciences Inc.

1. Quick Overview

1.1. Quick analysis of Cytek Biosciences Inc (30 sec.)










1.2. What can you expect buying and holding a share of Cytek Biosciences Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
20.0%

What is your share worth?

Current worth
$2.98
Expected worth in 1 year
$2.95
How sure are you?
35.0%

+ What do you gain per year?

Total Gains per Share
$-0.03
Return On Investment
-0.7%

For what price can you sell your share?

Current Price per Share
$3.65
Expected price per share
$3.27 - $4.66
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Cytek Biosciences Inc (5 min.)




Live pricePrice per Share (EOD)
$3.65
Intrinsic Value Per Share
$-1.10 - $-1.33
Total Value Per Share
$1.88 - $1.65

2.2. Growth of Cytek Biosciences Inc (5 min.)




Is Cytek Biosciences Inc growing?

Current yearPrevious yearGrowGrow %
How rich?$395.7m$414m-$23.3m-6.0%

How much money is Cytek Biosciences Inc making?

Current yearPrevious yearGrowGrow %
Making money-$1.5m-$3m$1.5m101.8%
Net Profit Margin-1.4%-7.8%--

How much money comes from the company's main activities?

2.3. Financial Health of Cytek Biosciences Inc (5 min.)




2.4. Comparing to competitors in the Medical Devices industry (5 min.)




  Industry Rankings (Medical Devices)  


Richest
#68 / 307

Most Revenue
#116 / 307

Most Profit
#152 / 307

Most Efficient
#133 / 307
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Cytek Biosciences Inc?

Welcome investor! Cytek Biosciences Inc's management wants to use your money to grow the business. In return you get a share of Cytek Biosciences Inc.

First you should know what it really means to hold a share of Cytek Biosciences Inc. And how you can make/lose money.

Speculation

The Price per Share of Cytek Biosciences Inc is $3.65. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Cytek Biosciences Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Cytek Biosciences Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $2.98. Based on the TTM, the Book Value Change Per Share is $-0.01 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.03 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Cytek Biosciences Inc.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps0.072.0%-0.01-0.3%-0.02-0.6%0.000.0%0.000.0%
Usd Book Value Change Per Share0.082.1%-0.01-0.2%-0.03-0.9%0.154.1%0.154.1%
Usd Dividend Per Share0.000.0%0.000.0%0.000.1%0.000.0%0.000.0%
Usd Total Gains Per Share0.082.1%-0.01-0.2%-0.03-0.9%0.154.1%0.154.1%
Usd Price Per Share6.49-6.08-8.09-7.04-7.04-
Price to Earnings Ratio22.34-41.15--21.70-557.24-557.24-
Price-to-Total Gains Ratio83.88--244.73--2,526.70--719.59--719.59-
Price to Book Ratio2.18-2.05-2.63-2.29-2.29-
Price-to-Total Gains Ratio83.88--244.73--2,526.70--719.59--719.59-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share3.65
Number of shares273
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.010.15
Usd Total Gains Per Share-0.010.15
Gains per Quarter (273 shares)-1.8340.81
Gains per Year (273 shares)-7.31163.23
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-7-171163153
20-15-241325316
30-22-312488479
40-29-382651642
50-37-453814805
60-44-523976968
70-51-59411391131
80-58-66413021294
90-66-73514651457
100-73-80516271620

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share2.02.00.050.0%5.07.00.041.7%12.08.00.060.0%12.08.00.060.0%12.08.00.060.0%
Book Value Change Per Share1.03.00.025.0%3.09.00.025.0%7.010.03.035.0%7.010.03.035.0%7.010.03.035.0%
Dividend per Share0.00.04.00.0%4.00.08.033.3%4.00.016.020.0%4.00.016.020.0%4.00.016.020.0%
Total Gains per Share1.03.00.025.0%3.09.00.025.0%7.010.03.035.0%7.010.03.035.0%7.010.03.035.0%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Cytek Biosciences Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.077-0.007+109%-0.034+144%0.149-48%0.149-48%
Book Value Per Share--2.9802.961+1%3.076-3%2.120+41%2.120+41%
Current Ratio--5.8596.600-11%7.407-21%7.405-21%7.405-21%
Debt To Asset Ratio--0.2080.205+1%0.199+5%0.286-27%0.286-27%
Debt To Equity Ratio--0.2620.258+2%0.248+6%0.155+69%0.155+69%
Dividend Per Share----0%0.002-100%0.000-100%0.000-100%
Enterprise Value--1035876232.480977266204.463+6%1271945471.980-19%1559372391.999-34%1559372391.999-34%
Eps--0.073-0.012+116%-0.022+130%-0.001+102%-0.001+102%
Ev To Ebitda Ratio---105.572-31.283-70%-50.686-52%287.698-137%287.698-137%
Ev To Sales Ratio--7.6965.716+35%6.808+13%9.530-19%9.530-19%
Free Cash Flow Per Share--0.0080.041-80%0.001+468%0.006+40%0.006+40%
Free Cash Flow To Equity Per Share---0.0190.012-266%-0.078+304%0.117-116%0.117-116%
Gross Profit Margin---0.231-1.808+681%2.170-111%-2.977+1187%-2.977+1187%
Intrinsic Value_10Y_max---1.332--------
Intrinsic Value_10Y_min---1.104--------
Intrinsic Value_1Y_max---0.017--------
Intrinsic Value_1Y_min---0.017--------
Intrinsic Value_3Y_max---0.140--------
Intrinsic Value_3Y_min---0.131--------
Intrinsic Value_5Y_max---0.369--------
Intrinsic Value_5Y_min---0.335--------
Market Cap467554050.000-84%861778232.480802331954.463+7%1087421971.980-21%935080574.400-8%935080574.400-8%
Net Profit Margin--0.287-0.014+105%-0.078+127%0.032+804%0.032+804%
Operating Margin---0.154-0.123-20%-0.107-31%-0.005-97%-0.005-97%
Operating Ratio--1.6191.281+26%1.162+39%1.053+54%1.053+54%
Pb Ratio1.225-78%2.1782.052+6%2.630-17%2.293-5%2.293-5%
Pe Ratio12.565-78%22.34241.152-46%-21.703+197%557.245-96%557.245-96%
Price Per Share3.650-78%6.4906.080+7%8.093-20%7.043-8%7.043-8%
Price To Free Cash Flow Ratio110.756-78%196.93378.563+151%16.903+1065%-261.860+233%-261.860+233%
Price To Total Gains Ratio47.174-78%83.880-244.732+392%-2526.696+3112%-719.593+958%-719.593+958%
Quick Ratio--7.6507.598+1%8.514-10%7.340+4%7.340+4%
Return On Assets--0.019-0.003+117%-0.006+129%0.001+3619%0.001+3619%
Return On Equity--0.024-0.004+116%-0.007+129%0.019+26%0.019+26%
Total Gains Per Share--0.077-0.007+109%-0.032+141%0.149-48%0.149-48%
Usd Book Value--395737000.000390734250.000+1%414056750.000-4%282409550.000+40%282409550.000+40%
Usd Book Value Change Per Share--0.077-0.007+109%-0.034+144%0.149-48%0.149-48%
Usd Book Value Per Share--2.9802.961+1%3.076-3%2.120+41%2.120+41%
Usd Dividend Per Share----0%0.002-100%0.000-100%0.000-100%
Usd Enterprise Value--1035876232.480977266204.463+6%1271945471.980-19%1559372391.999-34%1559372391.999-34%
Usd Eps--0.073-0.012+116%-0.022+130%-0.001+102%-0.001+102%
Usd Free Cash Flow--1094000.0005461250.000-80%113500.000+864%703750.000+55%703750.000+55%
Usd Free Cash Flow Per Share--0.0080.041-80%0.001+468%0.006+40%0.006+40%
Usd Free Cash Flow To Equity Per Share---0.0190.012-266%-0.078+304%0.117-116%0.117-116%
Usd Market Cap467554050.000-84%861778232.480802331954.463+7%1087421971.980-21%935080574.400-8%935080574.400-8%
Usd Price Per Share3.650-78%6.4906.080+7%8.093-20%7.043-8%7.043-8%
Usd Profit--9643000.000-1504750.000+116%-3037000.000+131%413750.000+2231%413750.000+2231%
Usd Revenue--33652000.00044157250.000-24%48253500.000-30%37723400.000-11%37723400.000-11%
Usd Total Gains Per Share--0.077-0.007+109%-0.032+141%0.149-48%0.149-48%
 EOD+4 -4MRQTTM+23 -15YOY+19 -215Y+19 -2110Y+19 -21

3.3 Fundamental Score

Let's check the fundamental score of Cytek Biosciences Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1512.565
Price to Book Ratio (EOD)Between0-11.225
Net Profit Margin (MRQ)Greater than00.287
Operating Margin (MRQ)Greater than0-0.154
Quick Ratio (MRQ)Greater than17.650
Current Ratio (MRQ)Greater than15.859
Debt to Asset Ratio (MRQ)Less than10.208
Debt to Equity Ratio (MRQ)Less than10.262
Return on Equity (MRQ)Greater than0.150.024
Return on Assets (MRQ)Greater than0.050.019
Total6/10 (60.0%)

3.4 Technical Score

Let's check the technical score of Cytek Biosciences Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5038.948
Ma 20Greater thanMa 503.843
Ma 50Greater thanMa 1004.391
Ma 100Greater thanMa 2005.350
OpenGreater thanClose3.650
Total0/5 (0.0%)

4. In-depth Analysis

4.1 About Cytek Biosciences Inc

Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. The company offers aurora and northern lights systems delivers cell analysis; aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; enhanced small particle detection; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent cocktail preparation systems. It also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments. In addition, the company offers automated micro-sampling system and automated sample loader system, an automated loaders designed to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools. It serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. The company distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific regions; and through distributors or sales agents in Europe, Latin America, and the Middle East countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.

Fundamental data was last updated by Penke on 2025-04-12 23:44:03.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is overpriced.
Based on how much money comes from the company's main activities, the company is overpriced.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Cytek Biosciences Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Cytek Biosciences Inc to the Medical Devices industry mean.
  • A Net Profit Margin of 28.7% means that $0.29 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Cytek Biosciences Inc:

  • The MRQ is 28.7%. The company is making a huge profit. +2
  • The TTM is -1.4%. The company is making a loss. -1
Trends
Current periodCompared to+/- 
MRQ28.7%TTM-1.4%+30.1%
TTM-1.4%YOY-7.8%+6.4%
TTM-1.4%5Y3.2%-4.6%
5Y3.2%10Y3.2%0.0%
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ28.7%-3.9%+32.6%
TTM-1.4%-11.1%+9.7%
YOY-7.8%-18.4%+10.6%
5Y3.2%-12.7%+15.9%
10Y3.2%-11.8%+15.0%
4.3.1.2. Return on Assets

Shows how efficient Cytek Biosciences Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Cytek Biosciences Inc to the Medical Devices industry mean.
  • 1.9% Return on Assets means that Cytek Biosciences Inc generated $0.02 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Cytek Biosciences Inc:

  • The MRQ is 1.9%. Using its assets, the company is less efficient in making profit.
  • The TTM is -0.3%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ1.9%TTM-0.3%+2.3%
TTM-0.3%YOY-0.6%+0.2%
TTM-0.3%5Y0.1%-0.4%
5Y0.1%10Y0.1%0.0%
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ1.9%-2.3%+4.2%
TTM-0.3%-3.1%+2.8%
YOY-0.6%-4.0%+3.4%
5Y0.1%-2.9%+3.0%
10Y0.1%-3.5%+3.6%
4.3.1.3. Return on Equity

Shows how efficient Cytek Biosciences Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Cytek Biosciences Inc to the Medical Devices industry mean.
  • 2.4% Return on Equity means Cytek Biosciences Inc generated $0.02 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Cytek Biosciences Inc:

  • The MRQ is 2.4%. Using its investors money, the company is inefficient in making profit. -1
  • The TTM is -0.4%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ2.4%TTM-0.4%+2.8%
TTM-0.4%YOY-0.7%+0.3%
TTM-0.4%5Y1.9%-2.3%
5Y1.9%10Y1.9%0.0%
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ2.4%-1.9%+4.3%
TTM-0.4%-4.8%+4.4%
YOY-0.7%-4.9%+4.2%
5Y1.9%-4.2%+6.1%
10Y1.9%-5.5%+7.4%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Cytek Biosciences Inc.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Cytek Biosciences Inc is operating .

  • Measures how much profit Cytek Biosciences Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Cytek Biosciences Inc to the Medical Devices industry mean.
  • An Operating Margin of -15.4% means the company generated $-0.15  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Cytek Biosciences Inc:

  • The MRQ is -15.4%. The company is operating very inefficient. -2
  • The TTM is -12.3%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-15.4%TTM-12.3%-3.2%
TTM-12.3%YOY-10.7%-1.6%
TTM-12.3%5Y-0.5%-11.8%
5Y-0.5%10Y-0.5%0.0%
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ-15.4%-14.7%-0.7%
TTM-12.3%-14.8%+2.5%
YOY-10.7%-18.0%+7.3%
5Y-0.5%-11.3%+10.8%
10Y-0.5%-11.6%+11.1%
4.3.2.2. Operating Ratio

Measures how efficient Cytek Biosciences Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Medical Devices industry mean).
  • An Operation Ratio of 1.62 means that the operating costs are $1.62 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Cytek Biosciences Inc:

  • The MRQ is 1.619. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.281. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.619TTM1.281+0.338
TTM1.281YOY1.162+0.119
TTM1.2815Y1.053+0.228
5Y1.05310Y1.0530.000
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ1.6191.324+0.295
TTM1.2811.324-0.043
YOY1.1621.279-0.117
5Y1.0531.327-0.274
10Y1.0531.331-0.278
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Cytek Biosciences Inc.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Cytek Biosciences Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Medical Devices industry mean).
  • A Current Ratio of 5.86 means the company has $5.86 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Cytek Biosciences Inc:

  • The MRQ is 5.859. The company is very able to pay all its short-term debts. +2
  • The TTM is 6.600. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ5.859TTM6.600-0.741
TTM6.600YOY7.407-0.807
TTM6.6005Y7.405-0.805
5Y7.40510Y7.4050.000
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ5.8592.698+3.161
TTM6.6002.698+3.902
YOY7.4072.870+4.537
5Y7.4053.526+3.879
10Y7.4053.456+3.949
4.4.3.2. Quick Ratio

Measures if Cytek Biosciences Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Cytek Biosciences Inc to the Medical Devices industry mean.
  • A Quick Ratio of 7.65 means the company can pay off $7.65 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Cytek Biosciences Inc:

  • The MRQ is 7.650. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 7.598. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ7.650TTM7.598+0.052
TTM7.598YOY8.514-0.916
TTM7.5985Y7.340+0.257
5Y7.34010Y7.3400.000
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ7.6501.446+6.204
TTM7.5981.494+6.104
YOY8.5141.790+6.724
5Y7.3402.263+5.077
10Y7.3402.440+4.900
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Cytek Biosciences Inc.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Cytek Biosciences Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Cytek Biosciences Inc to Medical Devices industry mean.
  • A Debt to Asset Ratio of 0.21 means that Cytek Biosciences Inc assets are financed with 20.8% credit (debt) and the remaining percentage (100% - 20.8%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Cytek Biosciences Inc:

  • The MRQ is 0.208. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.205. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.208TTM0.205+0.003
TTM0.205YOY0.199+0.006
TTM0.2055Y0.286-0.080
5Y0.28610Y0.2860.000
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2080.400-0.192
TTM0.2050.401-0.196
YOY0.1990.381-0.182
5Y0.2860.436-0.150
10Y0.2860.455-0.169
4.5.4.2. Debt to Equity Ratio

Measures if Cytek Biosciences Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Cytek Biosciences Inc to the Medical Devices industry mean.
  • A Debt to Equity ratio of 26.2% means that company has $0.26 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Cytek Biosciences Inc:

  • The MRQ is 0.262. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.258. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.262TTM0.258+0.004
TTM0.258YOY0.248+0.010
TTM0.2585Y0.155+0.103
5Y0.15510Y0.1550.000
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2620.552-0.290
TTM0.2580.600-0.342
YOY0.2480.560-0.312
5Y0.1550.654-0.499
10Y0.1550.721-0.566
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Cytek Biosciences Inc generates.

  • Above 15 is considered overpriced but always compare Cytek Biosciences Inc to the Medical Devices industry mean.
  • A PE ratio of 22.34 means the investor is paying $22.34 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Cytek Biosciences Inc:

  • The EOD is 12.565. Based on the earnings, the company is underpriced. +1
  • The MRQ is 22.342. Based on the earnings, the company is fair priced.
  • The TTM is 41.152. Based on the earnings, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD12.565MRQ22.342-9.777
MRQ22.342TTM41.152-18.810
TTM41.152YOY-21.703+62.855
TTM41.1525Y557.245-516.093
5Y557.24510Y557.2450.000
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
EOD12.565-1.035+13.600
MRQ22.342-1.266+23.608
TTM41.152-1.632+42.784
YOY-21.703-3.081-18.622
5Y557.245-2.816+560.061
10Y557.245-2.084+559.329
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Cytek Biosciences Inc:

  • The EOD is 110.756. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is 196.933. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is 78.563. Based on how much money comes from the company's main activities, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD110.756MRQ196.933-86.177
MRQ196.933TTM78.563+118.370
TTM78.563YOY16.903+61.660
TTM78.5635Y-261.860+340.423
5Y-261.86010Y-261.8600.000
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
EOD110.756-0.627+111.383
MRQ196.933-0.921+197.854
TTM78.563-1.650+80.213
YOY16.903-4.273+21.176
5Y-261.860-2.632-259.228
10Y-261.860-3.082-258.778
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Cytek Biosciences Inc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Medical Devices industry mean).
  • A PB ratio of 2.18 means the investor is paying $2.18 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Cytek Biosciences Inc:

  • The EOD is 1.225. Based on the equity, the company is underpriced. +1
  • The MRQ is 2.178. Based on the equity, the company is underpriced. +1
  • The TTM is 2.052. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD1.225MRQ2.178-0.953
MRQ2.178TTM2.052+0.126
TTM2.052YOY2.630-0.578
TTM2.0525Y2.293-0.241
5Y2.29310Y2.2930.000
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
EOD1.2251.680-0.455
MRQ2.1782.256-0.078
TTM2.0522.372-0.320
YOY2.6303.244-0.614
5Y2.2934.270-1.977
10Y2.2934.491-2.198
4.6.2. Total Gains per Share

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Cytek Biosciences Inc.

4.8.1. Institutions holding Cytek Biosciences Inc

Institutions are holding 61.329% of the shares of Cytek Biosciences Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-12-31BlackRock Inc14.42870.002418482795-9496-0.0514
2024-12-31Vanguard Group Inc9.14680.001311716843-61211-0.5197
2024-12-31Brown Capital Management, LLC6.43781.24028246610-1246864-13.1339
2024-12-31Hillhouse Capital Advisors, Ltd.5.19691.4964665703000
2024-12-31State Street Corp3.52110.001245103783428778.2274
2024-12-31Geode Capital Management, LLC2.06020.00132639083-28921-1.084
2024-12-31New York State Common Retirement Fund1.63030.0182208839000
2024-12-31Dimensional Fund Advisors, Inc.1.42890.0029183043226260716.7498
2024-12-31Wellington Management Company LLP1.18440.00181517214-489925-24.4091
2024-12-31Goldman Sachs Group Inc1.04740.0014134175231900831.1914
2024-12-31Northern Trust Corp0.92770.0011118833112126811.3647
2024-12-31Morgan Stanley - Brokerage Accounts0.85050.00051089461224032.0995
2024-12-31Charles Schwab Investment Management Inc0.82980.00131062990320283.1066
2024-12-31JPMorgan Chase & Co0.73980.0005947683-249391-20.8334
2024-12-31Millennium Management LLC0.62760.0026803923613314321.7655
2024-12-31Bank of New York Mellon Corp0.57040.0009730709116651.6223
2024-12-31FMR Inc0.53330.0003683187161112.4152
2024-12-31UBS Group AG0.51970.00086657336467893414.2156
2024-12-31Connor Clark & Lunn Inv Mgmt Ltd0.46970.0177601695-13935-2.2635
2024-12-31Principal Financial Group Inc0.39570.001850692537530.7459
Total 52.54672.794667311164+292080+0.4%

4.9.2. Funds holding Cytek Biosciences Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2025-03-31iShares Core S&P Small-Cap ETF5.16060.0338661060645840.0694
2025-02-28Vanguard Total Stock Mkt Idx Inv2.62840.0008336697500
2025-03-31iShares Russell 2000 ETF2.48420.02023182240-27555-0.8585
2025-02-28Vanguard Small Cap Index2.0540.0076263110721420.0815
2024-12-31Brown Capital Mgmt Small Co Inv1.89881.34792432313-1463130-37.56
2025-02-28Vanguard Institutional Extnd Mkt Idx Tr1.23770.0064158548626480.1673
2025-02-28Vanguard Small Cap Growth Index Inv1.15360.01791477673-5687-0.3834
2025-01-31Fidelity Small Cap Index0.92790.02251188625-22259-1.8382
2025-03-31iShares Russell 2000 Value ETF0.85180.04109110700
2025-03-31iShares S&P Small-Cap 600 Value ETF0.82820.06651060925-1048-0.0987
2025-03-31SPDR® Portfolio S&P 600™ Sm Cap ETF0.71830.033692015613440.1463
2025-03-31iShares Biotechnology ETF0.58240.0521746074-8310-1.1016
2025-02-28Vanguard Tax-Managed Small Cap Adm0.57360.03673472100
2025-02-28State St Russell Sm/Mid Cp® Indx NL Cl C0.570.007473014900
2025-03-31SPDR® S&P 600 Small Cap Value ETF0.50980.070165305313040.2001
2024-12-31Brown Capital Small Company0.46731.3723598572-58657-8.9249
2025-02-28Fidelity Extended Market Index0.44140.0064565453-3602-0.633
2025-02-28Vanguard Russell 2000 ETF0.43590.0208558387189823.5191
2025-02-28DFA US Small Cap I0.39450.0145053774705910.2678
2025-03-29Schwab US Small-Cap ETF™0.37730.012148325317500.3634
Total 24.29573.188431122252-1510435-4.9%

5.3. Insider Transactions

Insiders are holding 8.904% of the shares of Cytek Biosciences Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-04-19Ming YanSELL200005.87
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2023-12-312024-03-312024-06-302024-09-302024-12-31
Operating Income  -137-10,597-10,7342,207-8,5274,279-4,2487,2342,986



5.2. Latest Balance Sheet

Balance Sheet of 2024-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets499,500
Total Liabilities103,763
Total Stockholder Equity395,737
 As reported
Total Liabilities 103,763
Total Stockholder Equity+ 395,737
Total Assets = 499,500

Assets

Total Assets499,500
Total Current Assets396,446
Long-term Assets103,054
Total Current Assets
Cash And Cash Equivalents 98,716
Short-term Investments 179,145
Net Receivables 60,588
Inventory 43,893
Other Current Assets 14,104
Total Current Assets  (as reported)396,446
Total Current Assets  (calculated)396,446
+/-0
Long-term Assets
Property Plant Equipment 28,130
Goodwill 16,663
Intangible Assets 20,128
Long-term Assets Other 4,759
Long-term Assets  (as reported)103,054
Long-term Assets  (calculated)69,680
+/- 33,374

Liabilities & Shareholders' Equity

Total Current Liabilities67,663
Long-term Liabilities36,100
Total Stockholder Equity395,737
Total Current Liabilities
Short Long Term Debt 4,658
Accounts payable 5,529
Other Current Liabilities 33,083
Total Current Liabilities  (as reported)67,663
Total Current Liabilities  (calculated)43,270
+/- 24,393
Long-term Liabilities
Long term Debt 1,050
Capital Lease Obligations Min Short Term Debt11,308
Long-term Liabilities Other 11,400
Long-term Liabilities  (as reported)36,100
Long-term Liabilities  (calculated)23,758
+/- 12,342
Total Stockholder Equity
Common Stock129
Retained Earnings -35,199
Accumulated Other Comprehensive Income 16
Other Stockholders Equity 430,791
Total Stockholder Equity (as reported)395,737
Total Stockholder Equity (calculated)395,737
+/-0
Other
Capital Stock129
Cash and Short Term Investments 277,861
Common Stock Shares Outstanding 132,786
Current Deferred Revenue25,492
Liabilities and Stockholders Equity 499,500
Net Debt -91,164
Net Invested Capital 401,445
Net Working Capital 328,783
Property Plant and Equipment Gross 36,844
Short Long Term Debt Total 7,552



5.3. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-31
> Total Assets 
0
0
0
219,979
224,264
230,279
454,320
463,700
485,879
492,817
499,295
519,476
524,575
525,054
519,430
497,669
492,067
483,725
491,226
499,500
499,500491,226483,725492,067497,669519,430525,054524,575519,476499,295492,817485,879463,700454,320230,279224,264219,979000
   > Total Current Assets 
30,122
0
0
208,622
212,537
216,938
439,826
432,052
439,112
443,270
443,859
454,020
425,622
424,821
422,315
392,060
388,647
384,084
390,191
396,446
396,446390,191384,084388,647392,060422,315424,821425,622454,020443,859443,270439,112432,052439,826216,938212,537208,6220030,122
       Cash And Cash Equivalents 
-30,122
0
0
165,231
168,584
159,846
376,771
364,618
362,506
349,894
341,523
296,601
129,476
131,544
163,629
167,630
169,141
177,918
162,272
98,716
98,716162,272177,918169,141167,630163,629131,544129,476296,601341,523349,894362,506364,618376,771159,846168,584165,23100-30,122
       Short-term Investments 
60,244
0
0
0
0
0
0
0
0
0
0
44,548
169,519
167,294
124,392
95,111
101,298
99,323
115,505
179,145
179,145115,50599,323101,29895,111124,392167,294169,51944,548000000000060,244
       Net Receivables 
0
0
0
16,990
15,513
24,029
29,450
29,760
32,002
37,183
40,008
50,875
43,100
52,099
55,402
56,120
50,372
44,752
52,634
60,588
60,58852,63444,75250,37256,12055,40252,09943,10050,87540,00837,18332,00229,76029,45024,02915,51316,990000
       Other Current Assets 
0
0
0
3,383
2,222
6,408
6,094
5,311
6,622
10,848
12,959
13,842
16,786
8,153
11,458
12,653
13,094
12,051
12,980
14,104
14,10412,98012,05113,09412,65311,4588,15316,78613,84212,95910,8486,6225,3116,0946,4082,2223,383000
   > Long-term Assets 
-30,122
0
0
11,357
11,727
13,341
14,494
31,648
46,767
49,547
55,436
65,456
98,953
100,233
97,115
105,609
103,420
99,641
101,035
103,054
103,054101,03599,641103,420105,60997,115100,23398,95365,45655,43649,54746,76731,64814,49413,34111,72711,35700-30,122
       Property Plant Equipment 
0
0
0
2,140
2,476
3,895
4,982
5,851
20,343
20,975
22,260
27,565
28,736
28,011
29,118
29,258
28,196
27,442
28,632
28,130
28,13028,63227,44228,19629,25829,11828,01128,73627,56522,26020,97520,3435,8514,9823,8952,4762,140000
       Goodwill 
0
0
0
476
476
476
476
10,144
10,144
10,144
10,144
10,144
19,043
19,143
16,457
16,183
16,183
16,183
16,183
16,663
16,66316,18316,18316,18316,18316,45719,14319,04310,14410,14410,14410,14410,144476476476476000
       Intangible Assets 
0
0
0
274
274
333
361
4,739
4,328
3,859
4,485
4,331
24,764
23,683
24,292
23,084
22,252
21,420
20,492
20,128
20,12820,49221,42022,25223,08424,29223,68324,7644,3314,4853,8594,3284,739361333274274000
       Long-term Assets Other 
-30,122
0
0
1,089
1,123
1,259
1,297
1,665
1,264
2,880
2,959
2,957
1,406
1,409
1,568
1,785
2,481
3,320
4,950
4,759
4,7594,9503,3202,4811,7851,5681,4091,4062,9572,9592,8801,2641,6651,2971,2591,1231,08900-30,122
> Total Liabilities 
0
0
0
236,007
239,021
241,264
50,950
56,899
78,437
81,688
82,786
93,930
101,115
100,875
103,906
104,605
99,453
94,602
105,763
103,763
103,763105,76394,60299,453104,605103,906100,875101,11593,93082,78681,68878,43756,89950,950241,264239,021236,007000
   > Total Current Liabilities 
0
0
0
26,536
27,764
28,165
29,839
32,160
42,803
42,350
41,494
49,040
56,517
53,591
58,693
56,226
55,566
52,379
62,797
67,663
67,66362,79752,37955,56656,22658,69353,59156,51749,04041,49442,35042,80332,16029,83928,16527,76426,536000
       Short-term Debt 
0
0
0
2,772
2,772
11,593
10,578
15,251
2,214
2,529
1,413
3,511
3,585
3,492
12,893
14,328
4,218
12,309
0
0
0012,3094,21814,32812,8933,4923,5853,5111,4132,5292,21415,25110,57811,5932,7722,772000
       Short Long Term Debt 
0
0
0
2,772
2,772
0
0
0
0
0
0
580
582
551
548
565
1,939
1,926
1,997
4,658
4,6581,9971,9261,9395655485515825800000002,7722,772000
       Accounts payable 
0
0
0
2,944
3,361
3,324
3,927
3,034
5,971
6,749
5,640
4,805
5,280
3,082
4,711
3,032
3,725
3,191
5,389
5,529
5,5295,3893,1913,7253,0324,7113,0825,2804,8055,6406,7495,9713,0343,9273,3243,3612,944000
       Other Current Liabilities 
0
0
0
19,786
17,141
23,888
24,945
18,169
30,556
21,790
33,292
24,516
27,573
44,851
25,843
26,758
46,903
22,455
30,305
33,083
33,08330,30522,45546,90326,75825,84344,85127,57324,51633,29221,79030,55618,16924,94523,88817,14119,786000
   > Long-term Liabilities 
0
0
0
209,471
211,257
213,099
21,111
24,739
35,634
39,338
41,292
44,890
44,598
47,284
45,213
48,379
43,887
42,223
42,966
36,100
36,10042,96642,22343,88748,37945,21347,28444,59844,89041,29239,33835,63424,73921,111213,099211,257209,471000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
2,271
2,133
1,882
0
0
0
0
0
0
0000001,8822,1332,27100000000000
       Warrants
0
0
0
0
0
194,319
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000194,31900000
       Other Liabilities 
0
0
0
0
16,938
18,780
21,111
24,739
22,950
27,022
26,966
30,307
0
34,569
0
0
0
0
0
0
00000034,569030,30726,96627,02222,95024,73921,11118,78016,9380000
       Deferred Long Term Liability 
0
0
0
0
0
6,317
7,741
9,790
7,199
11,020
10,407
13,124
13,012
16,054
0
0
0
0
0
0
00000016,05413,01213,12410,40711,0207,1999,7907,7416,31700000
> Total Stockholder Equity
32,952
0
0
-16,028
-15,072
-11,300
403,055
406,458
407,236
411,027
416,447
425,295
423,460
424,179
415,524
393,064
392,614
389,123
385,463
395,737
395,737385,463389,123392,614393,064415,524424,179423,460425,295416,447411,027407,236406,458403,055-11,300-15,072-16,0280032,952
   Common Stock
0
0
0
23
24
24
125
126
134
135
135
135
136
136
136
131
131
132
130
129
129130132131131136136136135135135134126125242423000
   Retained Earnings -35,199-44,840-45,781-35,347-29,178-34,681-28,225-23,837-17,030-20,559-22,225-21,627-18,190-18,240-19,835-22,505-22,607000
   Capital Surplus 
0
0
0
0
0
7,975
420,600
423,625
427,818
432,889
437,401
442,887
447,748
454,027
0
0
0
0
0
0
000000454,027447,748442,887437,401432,889427,818423,625420,6007,97500000
   Treasury Stock00000000000000000000
   Other Stockholders Equity 
-41,701
0
0
-194,319
-194,319
-186,344
420,600
423,625
427,818
432,889
437,401
442,887
447,748
454,027
451,648
423,386
429,384
434,967
430,072
430,791
430,791430,072434,967429,384423,386451,648454,027447,748442,887437,401432,889427,818423,625420,600-186,344-194,319-194,31900-41,701



5.4. Balance Sheets

Currency in USD. All numbers in thousands.




5.5. Cash Flows

Currency in USD. All numbers in thousands.




5.6. Income Statements

Currency in USD. All numbers in thousands.


5.7. Latest Income Statement

Income Statement (annual), 2024-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue200,453
Cost of Revenue-89,347
Gross Profit111,106111,106
 
Operating Income (+$)
Gross Profit111,106
Operating Expense-131,629
Operating Income-20,523-20,523
 
Operating Expense (+$)
Research Development39,402
Selling General Administrative43,113
Selling And Marketing Expenses49,114
Operating Expense131,629131,629
 
Net Interest Income (+$)
Interest Income10,360
Interest Expense-5,239
Other Finance Cost-5,239
Net Interest Income10,360
 
Pretax Income (+$)
Operating Income-20,523
Net Interest Income10,360
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-5,700-35,346
EBIT - interestExpense = -5,239
-5,700
-781
Interest Expense5,239
Earnings Before Interest and Taxes (EBIT)0-461
Earnings Before Interest and Taxes (EBITDA)-20,523
 
After tax Income (+$)
Income Before Tax-5,700
Tax Provision-320
Net Income From Continuing Ops-6,020-6,020
Net Income-6,020
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses220,976
Total Other Income/Expenses Net14,823-10,360
 

Technical Analysis of Cytek Biosciences Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Cytek Biosciences Inc. The general trend of Cytek Biosciences Inc is BEARISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Cytek Biosciences Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-100.0%) Bearish trend (100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Cytek Biosciences Inc Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Cytek Biosciences Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 3.8 < 4.61 < 4.66.

The bearish price targets are: 3.27.

Know someone who trades $CTKB? Share this with them.👇

Cytek Biosciences Inc Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Cytek Biosciences Inc. The current mas is .

The long score for the Moving Averages is 0/14.
The longshort score for the Moving Averages is -14/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Cytek Biosciences Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Cytek Biosciences Inc. The current macd is -0.21896707.

The long score for the Moving Average Convergence/Divergence (MACD) is 3/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 2/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Cytek Biosciences Inc price going up in the near term. +2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Cytek Biosciences Inc. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Cytek Biosciences Inc price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Cytek Biosciences Inc Daily Moving Average Convergence/Divergence (MACD) ChartCytek Biosciences Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Cytek Biosciences Inc. The current adx is 39.69.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -4/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Cytek Biosciences Inc shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX > 25 && ADX trending up: The ADX is above 25 and indicates a strong bearish trend. The ADX is trending up, so the bearish trend is strengthening.
Cytek Biosciences Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Cytek Biosciences Inc. The current sar is 3.3008742.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Cytek Biosciences Inc Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Cytek Biosciences Inc. The current rsi is 38.95. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending down: The RSI is trending down. -1
Cytek Biosciences Inc Daily Relative Strength Index (RSI) ChartCytek Biosciences Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Cytek Biosciences Inc. The current phase is Continuation in bear market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -4/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Cytek Biosciences Inc price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Cytek Biosciences Inc Daily Stochastic Oscillator ChartCytek Biosciences Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Cytek Biosciences Inc. The current cci is -75.80130103.

Cytek Biosciences Inc Daily Commodity Channel Index (CCI) ChartCytek Biosciences Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Cytek Biosciences Inc. The current cmo is -17.66209244.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Cytek Biosciences Inc Daily Chande Momentum Oscillator (CMO) ChartCytek Biosciences Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Cytek Biosciences Inc. The current willr is -54.21686747.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Cytek Biosciences Inc is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Cytek Biosciences Inc Daily Williams %R ChartCytek Biosciences Inc Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Cytek Biosciences Inc.

Cytek Biosciences Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Cytek Biosciences Inc. The current atr is 0.23970491.

Cytek Biosciences Inc Daily Average True Range (ATR) ChartCytek Biosciences Inc Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Cytek Biosciences Inc. The current obv is 11,637,594.

Cytek Biosciences Inc Daily On-Balance Volume (OBV) ChartCytek Biosciences Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Cytek Biosciences Inc. The current mfi is 37.90.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Cytek Biosciences Inc Daily Money Flow Index (MFI) ChartCytek Biosciences Inc Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Cytek Biosciences Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-11-25STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-27STOCH SHORT EXITThe %K line crosses above the %D line.
2024-12-02ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-12-04WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-12-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-12-09SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-12-11STOCH LONG EXITThe %K line crosses below the %D line.
2024-12-12CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-12-13DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-12-16STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-12-17CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-12-18STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-12-19CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-12-20STOCH SHORT EXITThe %K line crosses above the %D line.
2024-12-23CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-12-27STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-12-30DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-01-03MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-01-07STOCH LONG EXITThe %K line crosses below the %D line.
2025-01-13STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-01-15MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-01-21STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-01-23STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-01-24STOCH SHORT EXITThe %K line crosses above the %D line.
2025-01-29STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-01-31CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-02-03STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-07STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-10CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-02-12STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-18MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2025-02-20STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-24STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-25STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-26CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-02-27MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-02-28STOCH SHORT EXITThe %K line crosses above the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-03STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-03-05RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-10STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-03-11CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-03-13STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-17MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2025-03-20SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-03-21STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-25STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-03-26CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-03-27STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-28STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-31STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-01STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-02STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-03STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-04-04STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-07MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-04-08STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-04-09RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-04-10STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-11MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-14SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2025-04-16STOCH LONG EXITThe %K line crosses below the %D line.

6.3. Candlestick Patterns

Cytek Biosciences Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Cytek Biosciences Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5038.948
Ma 20Greater thanMa 503.843
Ma 50Greater thanMa 1004.391
Ma 100Greater thanMa 2005.350
OpenGreater thanClose3.650
Total0/5 (0.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Cytek Biosciences Inc with someone you think should read this too:
  • Are you bullish or bearish on Cytek Biosciences Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Cytek Biosciences Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Cytek Biosciences Inc

I send you an email if I find something interesting about Cytek Biosciences Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Cytek Biosciences Inc.

Receive notifications about Cytek Biosciences Inc in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.